KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
91 hedge funds and large institutions have $237M invested in KalVista Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 36 increasing their positions, 22 reducing their positions, and 13 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 22
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
2% more funds holding
Funds holding: 89 → 91 (+2)
0.31% less ownership
Funds ownership: 99.16% → 98.85% (-0.31%)
35% less capital invested
Capital invested by funds: $364M → $237M (-$126M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$12.7M |
| 2 |
PVI
Pura Vida Investments
New York
|
+$8.51M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$7.23M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$6.51M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$28.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$18.3M |
| 3 |
DM
Deerfield Management
New York
|
-$12.2M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$9.67M |
| 5 |
State Street
Boston,
Massachusetts
|
-$5.83M |
KALV Hedge Fund Activity: Q2 2022 in Review
91 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q2 2022, worth a combined $237M — down 35% from $364M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new KALV positions and 13 closed out — a net gain of 4 holders — while 36 added to existing stakes and 22 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $12.7M. The largest seller was RA Capital Management, exiting entirely with an estimated $28.5M sold.
- 91 institutional investors held KalVista Pharmaceuticals (KALV) as of Q2 2022, up from 89 in Q1 2022.
- Funds reported $237M of KalVista Pharmaceuticals stock for Q2 2022, down 35% quarter-over-quarter.
- 17 funds opened new KalVista Pharmaceuticals positions in Q2 2022 and 13 closed out, a net change of +4 holders.
- The largest KalVista Pharmaceuticals buyer in Q2 2022 was Tang Capital Management, an estimated $12.7M added.
- The largest KalVista Pharmaceuticals seller in Q2 2022 was RA Capital Management, an estimated $28.5M sold.
Based on aggregated 13F filings for Q2 2022.